FDA
Articles tagged with “FDA”
FDA Clears Trial Pairing Ketamine Follow-Up Drug With TMS
The FDA cleared the MIND1 trial testing NRX-101 with robotic TMS for treatment-resistant depression and suicidality. What ketamine patients should know.
FDA Fast-Tracks Psychedelics for Depression, PTSD, and AUD
The FDA is accelerating psychedelic drug development for treatment-resistant depression, PTSD, and AUD. What it means for patients exploring ketamine therapy.
Trump Signs EO to Speed Psychedelic Research & Access
President Trump signed an executive order accelerating psychedelic research and access in April 2026. Here's what it means for ketamine therapy patients.
NRx's Preservative-Free Ketamine Moves Through FDA Review
NRx Pharmaceuticals reports progress on its FDA application for a preservative-free ketamine formulation. What patients should know about this development.
Psychedelics Executive Order: What It Means for Ketamine Patients
A new executive order targeting psychedelic medicines is reshaping the regulatory landscape. Here's what ketamine therapy patients should understand.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.